BioCentury
ARTICLE | Clinical News

QGC101: Phase IIa started

July 18, 2016 7:00 AM UTC

Quantum Genomics began the double-blind, placebo-controlled, European Phase IIa QUID HF trial to evaluate 50-500 mg oral QGC101 twice daily for 28 days in about 75 CHF patients with altered cardiac ej...